News | April 30, 2023
Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
Specialty Chemicals grew 38% YoY for FY23
Specialty Chemicals grew 38% YoY for FY23
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Clinical studies are expected to start in Q2 2023.
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Subscribe To Our Newsletter & Stay Updated
